lczuladapeds pk lecture HANDOUT nov2013.ppt

dadakobese 95 views 68 slides May 09, 2024
Slide 1
Slide 1 of 68
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59
Slide 60
60
Slide 61
61
Slide 62
62
Slide 63
63
Slide 64
64
Slide 65
65
Slide 66
66
Slide 67
67
Slide 68
68

About This Presentation

Pharmacokinetics


Slide Content

Pediatric Dosing of
Aminoglycosides and
VancomycinBased on
Pharmacokinetic Concepts
Marie Varela, Pharm.D., BCPS
ShereneSamu, Pharm.D.
1

Objectives
Describe basic pharmacokinetic parameters for
vancomycinand aminoglycosides in pediatric patients
Outline dosing strategies for aminoglycosidesbased
on pharmacokinetic principles
Outline dosing strategies for vancomycinbased on
pharmacokinetic principles
Select a monitoring plan for vancomycinand
aminoglycosides in pediatric patients
Select an adjusted dosing regimen based on serum
concentrations for vancomycinand aminoglycosides in
pediatric patients
2

Pharmacokinetics
Definition:
The study of the time course of a drug and its
metabolites in the body
The study of the ADME of a drug and its
metabolites in the body
Absorption
Distribution
Metabolism
Excretion
Varies greatly with age groups (pediatrics,
geriatrics)
3

Volume of Distribution
4

Excretion
Because of the PK and PD characteristics
of vancomycinand aminoglycosides, the
clearance of these drugs is closely
correlated to creatinineclearance
5

Estimation of CreatinineClearance
Schwartz Estimate
Estimates creatinineclearance
from serum creatinine, the
patient's height, and a
proportionality constant
CrCl= (k * Ht) / Cr
(Caution: formula tends to
overestimate the actual
creatinineclearance and
should be used with caution.)
http://www-users.med.cornell.edu
Htheight in
centimeters
Crserum creatinine
KConstant:
(see below)
Infant (LBW < 1
year)
0.33
Infant (Term < 1
year)
0.45
Child or Adolescent
Girl
0.55
Adolescent Boy 0.70
6

Elimination Half-life (t½)
Associated with first-order kinetics (serum
concentration diminishes logarithmically
over time)
Time it takes for plasma concentration to
reach half of a previous concentration
Affected by metabolism and excretion
Most drugs follow first-order kinetics
(including aminoglycosides and vanco)
7

Steady State
Equilibrium reached:
Rate of drug in=Rate of drug out
Time to reach steady state is a function of t½
t½ % of Steady State Achieved
1 50%
2 75%
3 87.5%
4 93.75%
5 100%
8

Graph of Multiple Dosing
Q6h dosing
t½ = 6 hours
9

PharmacodynamicConcepts Affecting
Dosing and Monitoring of
Aminoglycosidesand Vancomycin
Organism (Gram + vs. Gram -)
MIC of organism
Site of infection
Dose-response relationships of Abx
Concentration vs. time dependent bactericidal
activity
PAE
10

Concentration Dependent
Aminoglycosides
CONCENTRATION dependent killing
Maximize INTENSITY of exposure
As concentration at site ↑, antimicrobial action ↑
More pronounced responses to dosage
adjustments
11

Gentamicin/Tobramycin
Initial Dosing Pediatrics
12
ConventionalDosing Extended IntervalDosing
2-2.5 mg/kg/dose q8h 4.5-7.5 mg/kg/dose q24h
CF: 3.3 mg/kg/dose q8h CF: 10-12 mg/kg/dose q24h
Gram + synergy: 1 mg/kg/dose q8h N/A
Lexicomp 1978-2013

Gentamicin/Tobramycin
Initial Neonatal Dosing SBUH
PMA (weeks)Postnatal (days)Dose
(mg/kg)
Interval
(hours)
≤ 29 0 to 7
8 to 28
> 28
5
4
4
48
36
24
30 to 34 0 to 7
> 7
4.5
4
36
24
≥ 35 ALL 4 24
Reference: Neofax 13

Gentamicin/Tobramycin
Expected Half-Life
(Population Statistics)
Age t½
Neonates < 1wk 3 to 11.5 hrs
Neonates 1wk-1mo3 to 6 hrs
Infants 4 ±1 hrs
Children 2 ±1 hrs
Adolescents 1.5 ±1 hrs
Adults Normal Renal Function: 2 to 3 hr
Functionally Anephric: 30 to 60 hr
Clearance approximately equal to CrCl (≈ 5% metabolized)
14

AminoglycosidesTarget Goals
Tobramycin/Gentamicin
Target Serum Concentrations
Parameter
Serum
Concentration
Condition
Peak
4-5 mcg/mL
•UTI
•Gram (+) synergy
6-8 mcg/mL
•Pneumonia (within 24
to 48 hours)
Trough <2 mcg/mLto minimize toxicities
15

Time Dependent
Vancomycin
TIME dependent killing
Maximize DURATION of exposure
More pronounced responses to interval
adjustments
16

Vancomycin
Initial Dosing Pediatrics
10-15 mg/kg/dose q6-8 hours
Renal impairment
GFR 30-50: 10 mg/kg/dose q12h
GFR 10-29: 10 mg/kg/dose q18-24 hours
GFR < 10: 10 mg/kg/dose; re-dose based on
serum concentrations
17
Lexicomp 1978-2013

IV Vancomycin
Initial Neonatal Dosing SBUH
PMA
(weeks)
Postnatal (days) Interval
≤ 29 0 to 14
> 14
18
12
30 to 36 0 to 14
> 14
12
8
37 to 44 0 to 7
> 7
12
8
> 44 All 6
Dose: 10 to 15 mg/kg/dose*
(*This dosing strategy targets a trough of 5-15, therefore 15 mg/kg/dose is preferred.)
Reference: Neofax

Vancomycin
Expected Half-Life
(Population Statistics)
Age t
1/2
Neonates6 to 10 hrs
Infants3 to 4 hrs
Children2.2 to 3 hrs
Adults Normal renal function: 5-11 hr
End stage renal: 5 to 7 days
Clearance approximately equal to CrCl (≈ 5% metabolized)
19

IV Vancomycin
Target Serum Concentrations
Trough
Goal
Condition
10-15 mcg/mL•General
15-20 mcg/mL•Peritonitis
•Osteomyelitis
•MRSA pneumonia
•CNS infections
20
Maintain trough in therapeutic range; peak inconsequential

IV Vancomycin
Dosing Strategies
Due to pharmacodynamiccharacteristics,
optimal give more frequently
Want trough to remain in therapeutic range;
peak inconsequential
For renal impairment, reduce frequencies
21

Why Monitor?
Constant changes in Vdand clearance
Optimize therapeutic effects
Minimize toxicity
22

When to Monitor?
At presumed steady state
Upon initiation of therapy
After a dosage/frequency adjustment
Upon significant change in weight, fluid status, renal
function
After addition of a medication that may affect renal
function (i.e. Ibuprofen)
Every week after achieving therapeutic serum
concentrations
For vancomycindoses of > 15 mg/kg/dose q6h or > 3 g
per day, recheck first therapeutic trough in 2-3 days.
(Then follow above monitoring strategy thereafter.)
23

Time to Draw
Peak (aminoglycosidesonly)
30 minutes after dose completely infused
Trough (all drugs)
30 minutes before the next dose is due
24

How to Interpret Lab Results
Questions to ask yourself
Was the initial dosing appropriate? (considering renal
function etc.)
Was the trough drawn at presumed steady state?
For unexpected high concentrations, was it possible
the trough was drawn after the start of the infusion or
from a line that may not have been flushed?
Was it actually drawn at the time documented in the
system?
Should the level be redrawn?
25

Gentamicin Conventional Dosage
Adjustment Guidelines
26
If Peak is
High
(>10
mcg/mL)
Trough is High
Proportional DECREASE in DOSE to
bring peak to desired number.
Check to see how this change
affects trough.
If trough isstill high (above
range)with this dosage
decrease,DECREASE the
FREQUENCY.
Trough is in range
Proportional DECREASE in DOSE to
bring peak to desired number.
Trough is low
(<0.5 mcg/mL)
Proportional DECREASE in DOSE to
bring peak to desired numberand
INCREASE the dosing frequency.
If Peak is
Low
(less
than
target)
Trough is High
Proportional INCREASE in DOSE to
bring peak to desired number. Must
also DECREASE the dosing
frequency
Trough is in Range
Proportional INCREASE in DOSE to
bring peak to desired number.
Check to see how this change
affects the trough.
If the change will cause the
trough tobehigh (above
range), also DECREASE the
FREQUENCY.
Trough is low
Proportional INCREASE in DOSE to
bring peak to desired number.
Check to see how this change
affects trough.
If the change will cause the
trough tobehigh (above
range), also DECREASE the
FREQUENCY.

GentamicinDosage
Adjustment Guidelines
27
•If peak is in desired range and trough is
high, DECREASE THE FREQUENCY.
•After rechecking serum
concentrations, may be necessary to
increase dose with next adjustment.
•If peak is in desired range and trough is
low, most likely no adjustment is
necessary.

VancomycinDosage
Adjustment Guidelines
28
If trough
comes back
HIGH
If trough is in toxic
range, hold and draw
random serum
concentrations until
below 15 mcg/mL.
May calculate patient
half-life using formula if
there are 2
concentrations after a
dose and one value is at
least twice the other.
When
concentration is
below 15
mcg/mL,
recalculate
dose and
restart.
If half-life is
greater than
dosing interval,
increase dosing
interval to greater
than or equal to
one half-life
If trough
comes back
LOW
If trough is less than
half of target,
increase the
frequency. If the
frequency is already
Q6H, increase the
dose to 15 mg/kg. If
trough is still low,
increase the dose in
small increments
(i.e. 2 mg/kg per
dose)
If trough is more than
half of target, increase
the dose based on a
linear relationship;
calculate as a
proportional ratio to
trough. Maximum
increase of 50% at one
time.
Note: Q6h hours in the maximum frequency

Common Myth
Adjust the dose by 10%
Is this an appropriate recommendation?
In what situation, if ever, would this apply?
29

Calculating Actual Half-Life
to choose best dosage interval
K = ln C1
C2
ΔTime
t½= 0.693/K
K=elimination rate constant
Δ Time = hours

Can be done from random levels if spaced far enough apart
(one number at least twice the other)

Can be done from peak and trough if at steady state
30

Communication
Verbal
Progress notes
Sign outs
31

Case 1
Female
20 years old
ABW 76.6 kg
IBW 52.4 kg
SCr0.6
CrCl123 mL/min
Reason for visit
Chronic CSF leak
Comes to ER with symptoms of bending
down, having rhinorrhea
Started on vancomycin
Trough goal = 15-20 mcg/mL
32

Case 1
Date Dosing ScheduleDose Received Time
2/3/10 1 g x1 STAT 1 g 1629
2/4/10
1.5 g Q12H 1.5 g 0400
1 g Q12H 1 g 1520
2/5 /10
VANCOMYCIN TROUGH
10.1 mcg/mL
0330
1g Q12H
1 g 0400
1g 1530
33

Case 1
Pharmacy recommendation on 2/5/10
Draw a level on 2/6/10 AM
If level ≤ 10 mcg/mL, give 1 g Q8H
If level 11-12 mcg/mL, give 1.5 g Q12H
If 13-15 mcg/mL, give 1.2 g Q12h
34

Case 1
Date DosingScheduleDose Received Time
2/6/10
VANCOMYCIN TROUGH 11 mcg/mL 0300
1g Q12H 1 g 0330
1.5 g Q12H 1.5 g 1530
2/7/10 1.5 g Q12H
1.5 g 0330
1.5g 1530
2/8/10
VANCOMYCIN TROUGH
17.5 mcg/mL
0300
35

Case 2
Female
2 years old
ABW 17.5 kg
IBW 17.3 kg
SCr0.3
CrCl177 mL/min
Reason for admission
Lethargy
Mental status changes
Fever
Started on gentamicin
R/O sepsis (gram negative coverage)
36

Case 2
Target Serum Concentrations
Peak: 6-10 mcg/mL
Trough: < 2 mcg/mL
GentamicinDose: 2.5 mg per kg q8h
37

Case 2
Date Dosing ScheduleDose Received Time
1/27/10 43 mgQ8H 43 mg 22:00
1/28/10
43 mg Q8H 43mg 06:00
43 mg Q8H 43mg 14:00
1/28/10 Gentamicin Peak 5.2 mcg/mL 15:00
Gentamicin Trough 1.3 mcg/mL 21:30
1/28/10 43 mgQ8H 43 mg 22:00
38

Case 2
Dosage Adjustment
Want peak 6 or greater
If 43 mg yields peak of 5.2, what dose
would bring it to 6?
Use linear proportion as long as interval is
unchanged
39

Case 2
Dosage Adjustment Continued
What effect would that have on trough (if
dose was increased to 49 mg q8h)?
If 43 mg yields a trough of 1.3 mcg/mL, 49
mg would bring it to what trough?
40

Case 2
What if trough calculated to greater than 2?
Answer: increase the interval
Monitoring
After dosage change, repeat peak and trough
around 3
rd
dose of the new regimen
41

Case Study
Term neonate
DOB: 1/25/12
Diagnosis: chorioamnionitis
Weight 3.65 kg
Start antibiotics: ampicillin
gentamicin
42

Case 3 ( 1) Gentamicin
43
Gentamicinordered: 14.6 mg q 24 hours
Dosed at 4 mg per kg

Questions:
Was this dosed properly?
What criteria are used to determine if this
was dosed properly?
What level(s) will be drawn to properly
monitor this drug?
What serum concentrations are we
targeting?
44

GentamicinDosing
45
PMA (weeks)
Postnatal
(days)
Dose
(mg/kg)
Interval
(hours)
≤ 29 0 to 7
8 to 28
> 28
5
4
4
48
36
24
30 to 34 0 to 7
> 7
4.5
4
36
24
≥ 35 ALL 4 24
PMA is theequivalent to Gestational Age plus Postnatal Age

Case 3 (2) Gentamicin
46
Dose given each morning for 3 doses

Question:
What time should the peak be drawn?
What time should the trough be drawn?
47

Case 3 (3) Gentamicin
48

Case 3 (4) Gentamicin
49

Question:
What is your evaluation of this peak?
How do we proceed from here?
50

51
Date Dosage
Regimen
Admin
Time
Time
of
Blood
Draw
Peak,
Trough
or
Random
ResultSerum
Creat
Comments
1/25/12Gent
14.6 mg
q24
9:00 No serum creatinine.
Wt= 3.65 kg 4 mg/kg
1/26/12“ 8:08
1/27/12“ 8:089:00
(11:09)
Peak 33.7
Mcg/mL
If you “believe” these
numbers,
t ½ =1.88
12:39
(12:55)
Random9.3
Mcg/mL
Expected t ½ in
neonate=3-6 hours
Aminoglycoside Pharmacokinetic
Monitoring
Drug: Gentamicin

Case 3 (5) Gentamicin
52

53
Date Dosage
Regimen
Admin
Time
Time
of
Blood
Draw
Peak,
Trough
or
Random
ResultSerum
Creat
Comments
1/25/12Gent
14.6 mg
q24
9:00 No serum creatinine.
Wt= 3.65 kg 4 mg/kg
1/26/12“ 8:08
1/27/12“ 8:089:00
(11:09)
Peak 33.7
Mcg/mL
If you “believe” these
numbers,
t ½ =1.88
12:39
(12:55)
Random9.3
Mcg/mL
Expected t ½ in
neonate=3-6 hours
1/28/12 8:15 Trough1.6
Mcg/mL
Aminoglycoside Pharmacokinetic
Monitoring
Drug: Gentamicin

Question:
Next step?
Give a dose (4 mg/kg dose) now (9AM) and
draw a peak 30 minutes after it is infused
54

Case 3 (6)
55

Evaluation
Check initial dosing for correctness
Evaluate the credibility of the laboratory values
Identify possible reasons for serum
concentration to be different than what is
expected
Confirm that all doses were given as scheduled
Confirm that blood was drawn at the correct time
Repeat lab work if necessary
Make adjustments based on pharmacokinetic
relationships
56

Case 4 (1) Vancomycin
57
Dosed at 10 mg/kg per dose every 8 hours.
Prematureinfant is 3 weeks old when vancomycin
is added.
.

Case 4 (2) Vancomycin
58

Case 4 (3) Vancomycin
59
4th dose

Case 4 (4) Vancomycin
60

What is the next step?
Evaluate the initial dosing strategy
Evaluate the lab result
Target trough?
Adjust dose or change the frequency?
61

Summary
Basic knowledge of pharmacokinetics will
optimize prescribing by insuring:
Maximal therapeutic benefits
Minimal adverse effects
Cost effectiveness
Decreased blood sampling
62

CE Question #1
A patient is on vancomycinevery 8 hours
and his half life is 6 hours. What is the
earliest you would expect him to be at
steady state?
a)12 hours
b)6 hours
c)18 hours
d)24 hours
63

CE Question #2
A patient is on gentamicin being treated
for a gram negative pneumonia. What is
the target serum concentrations?
a)Peak 4; Trough <2
b)Peak 15; Trough <2
c)Peak 7; Trough <2
d)Peak 5; Trough <2
64

CE Question #3
A 4 year old female child with normal renal
function (Wt= 18 kg; Ht= 40 inch) is admitted
for presumed meningitis. What would be
the appropriate starting dose of
vancomycin?
a)1g q12h
b)15 mg/kg/dose q6h
c)5 mg/kg/dose q8h
d)750mg q6h
65

CE Question #4
There is a 10 kg patient that is on vancomycin150mg
q8h being treated for cellulitis. The trough comes back
at 5 at presumed steady state with all doses given at the
appropriate times. The resident calls down to the
pharmacy and asks you for a dosage adjustment. What
would be an appropriate recommendation?
a)Increase the dose by 10%
b)Change the frequency to q6h at the same dose
c)Increase the dose to 170mg at the same q8h frequency
d)Switch to linezolid because you don’t know how to adjust
vancomycin
66

Questions?
67

References
1.Harriet Lane Handbook.17
th
ed. Robertson, J and Shilkofski, N Editors.
Philadelphia: Mosby, Inc., 2005.
2.Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. 3
rd
ed. Appleton & Lange, 1993.
3.Thomson MICROMEDEX. 1974 -2008 MICROMEDEX(R) Thomson
Healthcare
4.Winter ME. Basic Clinical Pharmacokinetics. 4th ed. Baltimore: Lippincott
Williams & Wilkins, 2004.
5.http://www-users.med.cornell.edu
6.www.merck.com. Merck Manual on-line
7.Young, TE and Mangum, B. Neofax. 18
th
ed. Acorn Publishing, Raleigh,
2005.
8.Taketomo, Hoddong and Kraus. Pediatric Dosage Handbook. Lexi-comp.
2003-2004.
68
Tags